Dashboard
Manage Tickers

INCYINCYTE CORP

Nasdaq incyte.com


$ 53.09 $ 0.15 (0.28 %)    

Thursday, 02-May-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 53.09
$ 52.93
$ 53.09 x 100
$ 53.11 x 100
$ 52.29 - $ 53.42
$ 50.27 - $ 69.83
2,020,535
na
12.06B
$ 0.53
$ 16.18
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 02-13-2024 12-31-2023 10-K
3 10-31-2023 09-30-2023 10-Q
4 08-01-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 02-07-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-02-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-08-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-09-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-04-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-13-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 07-30-2019 06-30-2019 10-Q
21 04-30-2019 03-31-2019 10-Q
22 02-14-2019 12-31-2018 10-K
23 10-30-2018 09-30-2018 10-Q
24 07-31-2018 06-30-2018 10-Q
25 05-01-2018 03-31-2018 10-Q
26 02-15-2018 12-31-2017 10-K
27 10-31-2017 09-30-2017 10-Q
28 08-01-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-14-2017 12-31-2016 10-K
31 11-01-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 02-12-2016 12-31-2015 10-K
35 11-03-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-17-2015 12-31-2014 10-K
39 10-30-2014 09-30-2014 10-Q
40 07-31-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

td-cowen-maintains-buy-on-incyte-lowers-price-target-to-80
TD Cowen Maintains Buy on Incyte, Lowers P...
05/01/2024 17:56:09

TD Cowen analyst Marc Frahm maintains Incyte (NASDAQ:INCY) with a Buy and lowers the price target from $88 to $80.

truist-securities-reiterates-buy-on-incyte-lowers-price-target-to-83
Truist Securities Reiterates Buy on Incyte...
05/01/2024 12:47:51

Truist Securities analyst Srikripa Devarakonda reiterates Incyte (NASDAQ:INCY) with a Buy and lowers the price target from $...

bmo-capital-maintains-market-perform-on-incyte-lowers-price-target-to-52
BMO Capital Maintains Market Perform on In...
05/01/2024 12:01:58

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and lowers the price target from $56...

incyte-maintains-its-2024-jakafi-net-product-revenue-guidance-of-269b-275b-with-other-hematologyoncology-net-product-revenues-of-325m-360m
Incyte Maintains Its 2024 Jakafi Net Produ...
04/30/2024 11:04:33

incyte-q1-2024-adj-eps-064-misses-084-estimate-sales-880889-miss-926533m-estimate
Incyte Q1 2024 Adj EPS $0.64 Misses $0.84 ...
04/30/2024 11:02:22

Incyte (NASDAQ:INCY) reported quarterly earnings of $0.64 per share which missed the analyst consensus estimate of $0.84 by 23....

oppenheimer-maintains-outperform-on-incyte-lowers-price-target-to-84
Oppenheimer Maintains Outperform on Incyte...
04/24/2024 11:22:47

Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $92 to $84.

incyte-should-consider-significant-stock-buyback-and-prioritize-rd-analyst-recommends
Incyte Should Consider Significant Stock B...
04/23/2024 19:03:10

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a ...

peeling-back-the-layers-exploring-incyte-through-analyst-insights
Peeling Back The Layers: Exploring Incyte ...
04/23/2024 17:01:13

cantor-fitzgerald-initiates-coverage-on-incyte-with-neutral-rating
Cantor Fitzgerald Initiates Coverage On In...
04/23/2024 12:03:59

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Incyte (NASDAQ:INCY) with a Neutral rating.

incyte-to-acquire-escient-and-its-assets-for-750m-plus-escients-net-cash-remaining-at-the-close-of-the-transaction-subject-to-customary-adjustments
Incyte To Acquire Escient And Its Assets F...
04/23/2024 11:08:24

Incyte (NASDAQ:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small...

china-medical-system-announced-collaboration-and-license-agreement-with-incyte-for-selective-oral-smallmolecule-jak1-inhibitor-povorcitinib
China Medical System Announced Collaborati...
04/01/2024 10:40:18

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that ...

rbc-capital-reiterates-sector-perform-on-incyte-maintains-65-price-target
RBC Capital Reiterates Sector Perform on I...
03/25/2024 14:26:55

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $65 price target.

b-of-a-securities-maintains-neutral-on-incyte-lowers-price-target-to-67
B of A Securities Maintains Neutral on Inc...
03/13/2024 12:04:54

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Neutral and lowers the price target from $69 to...

stifel-reiterates-hold-on-incyte-maintains-68-price-target
Stifel Reiterates Hold on Incyte, Maintain...
03/12/2024 16:33:51

Stifel analyst Stephen Willey reiterates Incyte (NASDAQ:INCY) with a Hold and maintains $68 price target.

incyte-stock-a-deep-dive-into-analyst-perspectives-8-ratings
Incyte Stock: A Deep Dive Into Analyst Per...
03/12/2024 16:00:56

rbc-capital-reiterates-sector-perform-on-incyte-maintains-65-price-target
RBC Capital Reiterates Sector Perform on I...
03/12/2024 15:15:02

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $65 price target.

sunday-incyte-announced-results-from-a-phase-2-study-of-povorcitinib-incb54707-the-study-met-its-primary-endpoint-with-improvement-in-itch-compared-to-placebo-in-prurigo-nodularis
Sunday, Incyte Announced Results From A Ph...
03/11/2024 09:35:59

sunday-incyte-announced-new-results-from-phase-2-study-of-ruxolitinib-cream-opzelura-in-hidradenitis-suppurativa-the-study-met-its-primary-endpoint-demonstrating-significant-reduction-in-abscess-inflammatory-nodule-count-versus-vehicle-control
Sunday, Incyte Announced New Results From ...
03/11/2024 09:34:21

new-data-from-incytes-dermatology-portfolio-to-be-presented-at-the-2024-american-academy-of-dermatology-annual-meeting
New Data From Incyte's Dermatology Portfol...
03/04/2024 13:24:20

Two late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream...

incyte-announces-fda-grants-priority-review-for-axatilimab-for-chronic-graft-versus-host-disease
Incyte Announces FDA Grants Priority Revie...
02/27/2024 22:44:02

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION